Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE III 10 versus FREAMINE III 8 5 W ELECTROLYTES.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE III 10 versus FREAMINE III 8 5 W ELECTROLYTES.
FREAMINE III 10% vs FREAMINE III 8.5% W/ ELECTROLYTES
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FREAMINE III 10% is a parenteral amino acid solution that provides essential and non-essential amino acids for protein synthesis and nitrogen balance in patients unable to tolerate oral or enteral nutrition.
FREAMINE III 8.5% W/ ELECTROLYTES is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, promoting nitrogen balance and tissue maintenance in patients unable to tolerate oral/enteral nutrition.
Intravenous administration as part of parenteral nutrition. Typical adult dose: 0.8-1.5 g amino acids/kg/day, infused continuously over 24 hours.
Intravenous infusion: 1.0-1.5 g amino acids/kg/day (equivalent to 12-18 mL/kg/day of 8.5% solution). Administer via central or peripheral line. Typical adult dose: 500-1000 mL/day infused at 125-200 mL/hour.
None Documented
None Documented
Component-dependent: free amino acids t1/2 ~15–30 min; urea cycle intermediates ca. 2 h.
Not applicable as a composite mixture; individual amino acid half-lives vary from minutes to hours. Clinical context: continuous infusion used for metabolic support.
Primarily renal; amino acids and nitrogenous waste products are excreted as urea and other metabolites. <5% fecal.
Renal (primarily as urea and ammonia); 100% of infused amino acids are metabolized or excreted renally. Fecal excretion negligible.
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid